Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Clinical outcomes after ABO-incompatible renal transplantation - Authors' reply.

Scurt FG, Mertens PR, Chatzikyrkou C.

Lancet. 2019 Nov 30;394(10213):1989-1990. doi: 10.1016/S0140-6736(19)32592-9. No abstract available.

PMID:
31789215
2.

Systemic Inflammation Precedes Microalbuminuria in Diabetes.

Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H, Chatzikyrkou C; ROADMAP Steering Committee.

Kidney Int Rep. 2019 Jun 21;4(10):1373-1386. doi: 10.1016/j.ekir.2019.06.005. eCollection 2019 Oct.

3.

[The Cardiorenal Syndrome].

Scurt FG, Kuczera T, Mertens PR, Chatzikyrkou C.

Dtsch Med Wochenschr. 2019 Jul;144(13):910-916. doi: 10.1055/a-0768-5899. Epub 2019 Jun 28. German.

PMID:
31252445
4.

Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis.

Scurt FG, Ewert L, Mertens PR, Haller H, Schmidt BMW, Chatzikyrkou C.

Lancet. 2019 May 18;393(10185):2059-2072. doi: 10.1016/S0140-6736(18)32091-9. Epub 2019 Apr 18.

PMID:
31006573
5.

Predictors of Outcomes of Living Kidney Donation: Impact of Sex, Age and Preexistent Hypertension.

Chatzikyrkou C, Scurt FG, Clajus C, Roumeliotis S, Mertens PR, Haller H, Blume C, Liakopoulos V.

Transplant Proc. 2019 Mar;51(2):396-404. doi: 10.1016/j.transproceed.2019.01.015. Epub 2019 Jan 4.

PMID:
30879551
6.

Remission of nephrotic syndrome after resolution of renal artery stenosis in a patient with a single functional kidney.

Schiefer J, Chatzikyrkou C, Mertens PR, Liakopoulos V.

Clin Nephrol. 2019 Apr;91(4):265-267. doi: 10.5414/CN109542. No abstract available.

PMID:
30663976
7.

Unrecognized juvenile nephropathic cystinosis.

Schiefer J, Zenker M, Gröne HJ, Chatzikyrkou C, Mertens PR, Liakopoulos V.

Kidney Int. 2018 Nov;94(5):1027. doi: 10.1016/j.kint.2018.06.001. No abstract available.

PMID:
30348293
8.

Predictors for the development of microalbuminuria and interaction with renal function.

Chatzikyrkou C, Menne J, Izzo J, Viberti G, Rabelink T, Ruilope LM, Rump C, Mertens PR, Haller H.

J Hypertens. 2017 Dec;35(12):2501-2509. doi: 10.1097/HJH.0000000000001491.

PMID:
29035939
9.

Position-related renal perfusion disturbances as a possible underestimated mechanism in patients with resistant hypertension: a case vignette.

Schiefer J, Amthauer H, Genseke P, Mertens PR, Chatzikyrkou C.

Int Urol Nephrol. 2017 Oct;49(10):1823-1833. doi: 10.1007/s11255-017-1656-1. Epub 2017 Jul 11.

PMID:
28699016
10.

Midkine, a heparin-binding growth factor, and its roles in atherogenesis and inflammatory kidney diseases.

Şalaru DL, Arsenescu-Georgescu C, Chatzikyrkou C, Karagiannis J, Fischer A, Mertens PR.

Nephrol Dial Transplant. 2016 Nov;31(11):1781-1787. Epub 2016 May 17. Review.

PMID:
27190351
11.

Low-dose erythropoietin promotes wound-healing of ulcers in diabetics: Evidence from a phase-IIa clinical study.

Chatzikyrkou C, Bahlmann FH, Sushakova N, Scurt FG, Menne J, Nawroth P, Mertens PR, Haller H.

Diabetes Metab. 2016 Dec;42(6):466-470. doi: 10.1016/j.diabet.2016.05.010. Epub 2016 Jun 17. No abstract available.

PMID:
27324461
12.

Short- and long-term effects of the use of RAAS blockers immediately after renal transplantation.

Chatzikyrkou C, Eichler J, Karch A, Clajus C, Scurt FG, Ramackers W, Lehner F, Menne J, Haller H, Mertens PR, Schiffer M.

Blood Press. 2017 Feb;26(1):30-38. doi: 10.1080/08037051.2016.1182856. Epub 2016 May 19.

PMID:
27195820
13.

Effects of various stages of nephropathy on wound healing in patients with diabetes: an observational cohort study encompassing 731 diabetics.

Loewe P, Stefanidis I, Mertens PR, Chatzikyrkou C.

Int Urol Nephrol. 2016 May;48(5):751-8. doi: 10.1007/s11255-016-1229-8. Epub 2016 Feb 12.

PMID:
26873270
14.

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.

J Am Soc Nephrol. 2015 Aug;26(8):1999-2010. doi: 10.1681/ASN.2014050423. Epub 2015 Jan 14.

15.

Total collected dialysate lithium concentration after successful dialysis treatment in case of intoxication.

Schmidt JJ, Lorenzen J, Chatzikyrkou C, Lichtinghagen R, Kielstein JT.

BMC Pharmacol Toxicol. 2014 Sep 6;15:49. doi: 10.1186/2050-6511-15-49.

17.

Beyond C4d: the ultrastructural appearances of endothelium in ABO-incompatible renal allografts.

Bröcker V, Pfaffenbach A, Habicht A, Chatzikyrkou C, Kreipe HH, Haller H, Scheffner I, Gwinner W, Zilian E, Immenschuh S, Schwarz A, Horn PA, Heinemann FM, Becker JU.

Nephrol Dial Transplant. 2013 Dec;28(12):3101-9. doi: 10.1093/ndt/gft373. Epub 2013 Sep 29.

PMID:
24081856
18.

Diabetes: Legacy effects of RAS blockade in diabetes mellitus.

Chatzikyrkou C, Menne J.

Nat Rev Nephrol. 2013 Oct;9(10):566-8. doi: 10.1038/nrneph.2013.173. Epub 2013 Sep 10. No abstract available.

PMID:
24018412
19.

Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience.

Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, Bara CL, Gottlieb J, Wenzel J, Manns MP, Wedemeyer H.

Liver Int. 2013 May;33(5):722-6. doi: 10.1111/liv.12114. Epub 2013 Mar 13.

PMID:
23489973
20.

Targeting albuminuria in arterial hypertension and diabetes: how is it best achieved and what is its clinical relevance?

Chatzikyrkou C, Menne J.

J Hypertens. 2013 Jan;31(1):44-6. doi: 10.1097/HJH.0b013e32835c1604. No abstract available.

PMID:
23221930
21.

Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.

Chatzikyrkou C, Menne J.

Expert Rev Cardiovasc Ther. 2012 Sep;10(9):1087-92. doi: 10.1586/erc.12.100. Review.

PMID:
23098143
22.

Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.

Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, Dalekos GN, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group.

J Viral Hepat. 2012 Jun;19(6):387-95. doi: 10.1111/j.1365-2893.2011.01560.x. Epub 2011 Dec 19.

PMID:
22571900
23.

[Therapeutic targets in arterial hypertension and diabetes mellitus. Can medical prevention be harmful?].

Chatzikyrkou C, Haller H, Menne J.

Internist (Berl). 2012 Jul;53(7):882-92. doi: 10.1007/s00108-012-3071-0. German.

PMID:
22562111
24.

Diabetes: hyperfiltration-a risk factor for nephropathy in T1DM?

Chatzikyrkou C, Haller H.

Nat Rev Endocrinol. 2012 Apr 24;8(7):385-6. doi: 10.1038/nrendo.2012.63. No abstract available.

PMID:
22525729
25.

[Albuminuria : prognostic marker or therapeutic goal?].

Chatzikyrkou C, Haller H, Menne J.

Internist (Berl). 2012 Jan;53(1):38-44. doi: 10.1007/s00108-011-2891-7. German.

PMID:
22231694
26.

Pathogenesis and management of hypertension after kidney transplantation.

Chatzikyrkou C, Menne J, Gwinner W, Schmidt BM, Lehner F, Blume C, Schwarz A, Haller H, Schiffer M.

J Hypertens. 2011 Dec;29(12):2283-94. doi: 10.1097/HJH.0b013e32834bd1e7. Review.

PMID:
21970935
27.

Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis.

Metzger J, Chatzikyrkou C, Broecker V, Schiffer E, Jaensch L, Iphoefer A, Mengel M, Mullen W, Mischak H, Haller H, Gwinner W.

Proteomics Clin Appl. 2011 Jun;5(5-6):322-33. doi: 10.1002/prca.201000153. Epub 2011 Apr 29.

PMID:
21538920
28.

Hypercalcemia and pneumocystis Pneumonia after kidney transplantation: report of an exceptional case and literature review.

Chatzikyrkou C, Clajus C, Haubitz M, Hafer C.

Transpl Infect Dis. 2011 Oct;13(5):496-500. doi: 10.1111/j.1399-3062.2011.00623.x. Epub 2011 Mar 17. Review.

PMID:
21414118
29.

Biopsy proven acute interstitial nephritis after treatment with moxifloxacin.

Chatzikyrkou C, Hamwi I, Clajus C, Becker J, Hafer C, Kielstein JT.

BMC Nephrol. 2010 Aug 23;11:19. doi: 10.1186/1471-2369-11-19.

30.

Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade.

Menne J, Chatzikyrkou C, Haller H.

J Hypertens. 2010 Oct;28(10):1983-94. doi: 10.1097/HJH.0b013e32833c206d. Review.

PMID:
20634721
31.

[Hypertension 2007-2008].

Chatzikyrkou C, Menne J, Haller H.

Med Klin (Munich). 2009 Aug;104(8):614-21. doi: 10.1007/s00063-009-1133-4. Epub 2009 Aug 23. Review. German.

PMID:
19701732
32.

Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphteria-poliomyelitis-vaccination.

Clajus C, Spiegel J, Bröcker V, Chatzikyrkou C, Kielstein JT.

BMC Nephrol. 2009 Aug 5;10:21. doi: 10.1186/1471-2369-10-21. Review.

33.

The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril.

Chatzikyrkou C, Haller H, Menne J.

Expert Opin Pharmacother. 2009 Aug;10(11):1833-40. doi: 10.1517/14656560903055087. Review.

PMID:
19527194
34.

How to achieve renal protection in the light of ONTARGET?

Chatzikyrkou C, Menne J, Haller H.

J Hypertens Suppl. 2009 Jun;27(2):S15-7. doi: 10.1097/01.hjh.0000354514.59827.04.

PMID:
19491616

Supplemental Content

Loading ...
Support Center